NASDAQ$CRVS
Corvus Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Corvus Pharmaceuticals reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Corvus Pharmaceuticals reported a net loss of $8.4 million for the second quarter ended June 30, 2022, compared to a net loss of $11.8 million for the same period in 2021. As of June 30, 2022, Corvus had cash, cash equivalents and marketable securities totaling $56.7 million and expects its cash to fund operations into early 2024.
- Prioritizing the development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases.
- Plans to begin Phase 2 Clinical Trial of Ciforadenant in Front Line Renal Cell Cancer (RCC) in partnership with Kidney Cancer Consortium in Q3 2022.
- Pausing start of randomized Phase 2 Clinical Trial of Mupadolimab in Lung Cancer and extends cash runway into early 2024.
- Angel Pharmaceuticals is enrolling patients with relapsed T cell lymphomas (TCL) in Phase 1/1b trial evaluating single agent therapy with CPI-818.
Headline financials
Revenue & EPS history
Corvus Pharmaceuticals · Revenue · Quarterly
-$1.6M
Forward guidance
Corvus expects full year 2022 net cash used in operating activities to be between $27 million and $29 million, resulting in a projected cash balance of between $40.5 million and $42.5 million as of December 31, 2022. Based on its current plans, the Company expects its cash to fund operations into early 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.0%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+7.3%
Avg return
30 days after
53%
20 / 38 earnings
Positive
+32.2%
Q1 2025
Best reaction
-18.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +6.6% | +8.6% | — | |
| Q3 2025 | -1.4% | +3.5% | +15.3% | |
| Q2 2025 | +4.4% | +21.1% | +49.2% | |
| Q1 2025 | +32.2% | +8.1% | +16.7% | |
| Q4 2024 | -14.8% | -19.1% | -7.6% | |
| Q3 2024 | -7.2% | -14.3% | -15.5% | |
| Q1 2024 | -12.5% | +8.3% | +15.6% | |
| Q4 2023 | -2.6% | -5.8% | -25.8% | |
| Q3 2023 | +8.1% | -6.1% | +13.5% | |
| Q2 2023 | +10.5% | +7.2% | -21.5% | |
| Q1 2023 | +8.3% | +70.8% | +190.4% | |
| Q4 2022 | +11.1% | +40.0% | +75.4% | |
| Q3 2022 | -3.4% | -8.3% | +18.1% | |
| Q2 2022 | -5.0% | +12.4% | +11.4% | |
| Q1 2022 | -7.3% | -10.9% | -22.6% | |
| Q4 2021 | -8.5% | -11.5% | +4.8% | |
| Q3 2021 | +9.5% | +10.4% | -27.8% | |
| Q2 2021 | +0.5% | +1.9% | +11.5% | |
| Q1 2021 | -2.1% | -1.4% | -4.9% | |
| Q4 2020 | +7.3% | +2.8% | -1.7% | |
| Q3 2020 | +4.2% | +7.4% | +6.1% | |
| Q2 2020 | +1.9% | -1.7% | -12.7% | |
| Q1 2020 | -15.0% | +19.8% | +36.4% | |
| Q4 2019 | -18.4% | -27.5% | -47.9% | |
| Q3 2019 | -4.6% | -5.5% | -17.2% | |
| Q2 2019 | -3.1% | -9.0% | -12.8% | |
| Q1 2019 | +7.7% | +6.4% | -15.8% | |
| Q4 2018 | +0.0% | -6.0% | -8.5% | |
| Q3 2018 | +8.7% | -0.3% | -21.2% | |
| Q2 2018 | -6.8% | -7.0% | +12.8% | |
| Q1 2018 | -0.3% | +0.1% | +36.0% | |
| Q3 2017 | +4.2% | -1.8% | -18.6% | |
| Q2 2017 | +3.5% | -1.6% | +36.6% | |
| Q1 2017 | +3.2% | +2.0% | +16.9% | |
| Q4 2016 | +18.1% | +25.5% | -41.1% | |
| Q3 2016 | +3.7% | +8.7% | +17.1% | |
| Q2 2016 | +4.1% | +7.4% | +4.1% | |
| Q1 2016 | -5.4% | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro